Prevalence of Diabetes to Create Scope for North America Dipeptidyl peptidase 4 (DPP-4) inhibitors Market Growth

The North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.4% over the forecast period (2020-2026). The growth of the North America dipeptidyl peptidase 4 (DPP-4) inhibitors industry in the region is primarily driven by the increase in the number of cases of diabetes type 2 in the North American region. As per the International Diabetes Federation IDF 2019, over 31.0 million people were suffering from diabetes in the US and approximately 16 million people in Canada. The total number of cases in the US is projected to witness an upsurge owing to the changing lifestyles of the people, thus, it is projected by the IDF that in 2030 the total number of cases is expected to surpass 34.4 million and over 36.0 million cases in 2045. Thus, an increased number is likely to create a scope for market growth.

Browse the full report description of "North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others) Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market

However, there are severe side effects associated with the consumption of the drug is likely to challenge the growth of the market. Additionally, in 2015, the US FDA had warned regarding the intake of the DPP-4 inhibitors. It results in severe joint pain. Nevertheless, the drug can be taken with a specific diet and exercise for lowering the blood sugar levels in adults suffering from type 2 diabetes. Furthermore, the contributions by the key players in order to develop advanced and safe drugs may create significant scope for the market growth over the forecast period.

Market Coverage

• Market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type
• Regions Covered- North America
• Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in base year?
• Which segment will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North America Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation

By Type

• Sitagliptin
• Vildagliptin
• Saxagliptin 
• Linagliptin 
• Gemigliptin 
• Anagliptin
• Teneligliptin 
• Others

North America Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Countries Covered  

• US
• Canada

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market